Bright Minds Biosciences

DRUG · CANADIAN

$52.48−$0.21 (−0.40%)TodayMarket closed · Oct 23, 7:50 PM ET

Prev close $52.69

DRUG analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $8.80 (−83.2% downside)

Low: $8.71
Now: $52.48
High: $9.06

Upgrades and downgrades

The latest rating actions, newest first

DRUG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wolfe Research	Oct 15, 2026	Initiates	Outperform	$150.00	—
HC Wainwright & Co.	Aug 19, 2026	Maintains	Buy	$145.00	33%
BTIG	Aug 17, 2026	Maintains	Buy	$147.00	30%
HC Wainwright & Co.	Jun 1, 2026	Maintains	Buy	$145.00	33%
Piper Sandler	May 20, 2026	Maintains	Overweight	$190.00 → $220.00	37%
Jefferies	Apr 13, 2026	Initiates	Buy	$145.00	42%
BTIG	Mar 30, 2026	Maintains	Buy	$147.00	30%
HC Wainwright & Co.	Mar 4, 2026	Maintains	Buy	$115.00 → $145.00	33%
BTIG	Feb 17, 2026	Maintains	Buy	$147.00	30%
BTIG	Jan 7, 2026	Maintains	Buy	$72.00 → $147.00	30%

The case for and against

Updated Oct 21, 2026

Bull case

Bright Minds Biosciences is viewed favorably because BMB-101 delivered strong Phase 2 proof-of-concept in drug-resistant epilepsy, with a 73.1% median reduction in absence seizures (p=0.012), a 74.4% median drop in 24-hour seizure burden, and a 63.3% median reduction in major motor seizures in DEE patients. The data are especially compelling because seizures were measured by blinded ambulatory EEG rather than caregiver diaries, and the favorable tolerability profile plus lack of somnolence support the thesis that its highly selective 5-HT2C mechanism can translate into a differentiated chronic therapy. Beyond epilepsy, the company adds optionality through PWS and neuropsychiatry programs, while expected 2H26 registrational-study initiation offers a clearer de-risking path for the core asset.

Bear case

Bright Minds Biosciences is burdened by a highly speculative valuation that depends on DCF and SOTP assumptions, including 75% and 60% probabilities of success for BMB-101 in DEEs and absence epilepsy, respectively, alongside a 12% discount rate and a 6x terminal multiple. The model also assumes C$250 million of annual equity raises from FY2027E to FY2028E, signaling likely shareholder dilution and reinforcing the risk that financing needs could outpace clinical progress. With major downside tied to clinical, commercialization, competitor, novel modality, reimbursement, pricing, and business development risks, the investment case remains fragile despite an estimated total firm value of approximately $1.6 billion.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.